Treatment of DIO-NASH mice with ALT-801 resulted in greater reductions in most measures of NASH compared to either semaglutide or elafibranor, and ALT-801 administration significantly reduced the inflammatory marker Gal-3 and fibrosis marker Col1A1, with Gal-3 reduction at a greater degree than either comparator drug. The gene discussed is LGALS3; the disease is metabolic dysfunction-associated steatohepatitis.